Who is this relevant for?
- Hospitals managing supply risk
- Distributors monitoring sourcing opportunities
Italian pharma group Chiesi has agreed to acquire KalVista Pharmaceuticals for roughly $1.9bn, picking up sebetralstat, a first-in-class oral on-demand therapy for hereditary angioedema (HAE). The cash tender offer of $27 per share represents a 36% premium to KalVista’s recent trading average.
This is Chiesi’s largest acquisition to date. It signals a serious commitment to rare and ultra-rare disease, specifically through its Chiesi Global Rare Diseases unit. Sebetralstat is the first oral, on-demand option for HAE—a condition where current treatments are often injectable and used for prophylaxis or acute episodes. The new drug could shift how patients and clinicians manage the disease.
From an operational perspective, the deal adds a differentiated asset to Chiesi’s rare immunology portfolio and strengthens its US commercial footprint. Chiesi expects sebetralstat to contribute to its €6bn revenue target for 2030. The transaction is expected to close in Q3 2026, subject to tender of a majority of shares and regulatory approvals.
For hospitals and distributors, the arrival of an oral HAE therapy introduces a new product category. It may affect procurement strategies for existing injectable treatments and create opportunities for sourcing the new drug. Chiesi has stated it will work closely with the HAE community to support the transition and maximise real-world value.